Matrix metalloproteinases and their tissue inhibitors in diabetes, atherosclerosis and prediction of the cardiovascular risk

Current Enzyme Inhibition

Volumn 6, Issue 4, 2010, Pages 211-224

  Vargová, Viola ^a   Pytliak, Marek ^a   Mechírová, Viola ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Atherosclerosis; Cardiovascular risk; Matrix metalloproteinases; TIMPs

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BATIMASTAT; CORTICOSTEROID DERIVATIVE; FLUINDOSTATIN; GELATINASE A; GELATINASE B; ILOMASTAT; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PLACEBO; PROTEIN; RETINOID DERIVATIVE; ROSIGLITAZONE; SOLIMASTAT; STROMELYSIN; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTHRALGIA; ARTICLE; ARTIFICIAL EMBOLISM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG TARGETING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MORPHOLOGY; MUSCULOSKELETAL DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; ZYMOGRAPHY;

EID: 79953878488     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340810794578524     Document Type: Article

References (136)

1. Mott, J.D.; Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell. Biol., 2004, 16(5), 558-564.
2. Augustin, S.; Berard, M.; Kellaf, S.; Peyri, N.; Fauvel-Lefève, F.; Legrand, C.; He, L.; Crépin, M. Matrix metalloproteinases are involved in both type I (apoptosis) and type II (autophagy) cell death induced by sodium phenylacetate in MDA-MB-231 breast tumor cells. Anticancer Res., 2009, 29, 1335-1334.
3. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol., 2001, 17, 463-16.
4. Murphy, G.; Knauper V. Relating matrix metalloproteinase structure to function: Why the 'Hemopexin' domain? Matrix Biol., 1997, 15 (8-9), 511-518.
5. Woessner, J.F. Jr. The family of matrix metalloproteases. Ann. NY Acad. Sci., 1994, 732, 11-21.
6. Henney, A.M.; Ye, S.; Zhang, B.; Jormsjö, S.; Whatling, C.; Eriksson, P.; Hamsten, A. Genetic diversity in the matrix metalloproteinase family: effects on function and disease progression. Ann. NY Acad. Sci., 2000; 902, 27-37.
7. Borkakoti, N. Structural studies of matrix metalloproteinases. J. Mol. Med., 2000, 78, 261-268.
8. Nagase, H. Matrix metalloproteinases. In: Zinc metalloproteases in health and disease. Hooper NM, Ed. Taylor and Francis, London, 1996
9. Borkakoti, N.; Winkler, F.K.; Williams, D.H.; D'Arcy, A.; Broadhurst, M.J.; Brown, P.A.; Johnson, W.H.; Murray E.J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol.,1994, 1, 106-110.
10. Stoker, W.; Bode,W. Structural features of a superfamily of zincendopeptidases: the metzincins. Curr. Opin. Struct. Biol., 1995, 5, 383-390.
11. Chen, L.C.; Noelken, M.E.; Nagase, H. Disruption of the cysteine 75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin-1). Biochemistry, 1993, 32, 10289-10295.
12. van Wart, H.E.; Hansen-Birkedal, H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicabilityto the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA, 1990, 87, 5578-5582.
13. Nagase, H.; Woessner, J.F. Matrix metalloproteinases. J. Biol. Chem., 1999, 274, 21491-21494.
14. Lovejoy, B.; Welch, A.R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R.T.; Campbell, J.A.; Walker, K.A.; Martin, R.; van Wart, H.; Browner, M.F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol., 1999, 6, 217-221.
15. Netzel-Arnett, S.; Salari, A.; Goli, U.B.; van Wart H.E. Evidence for a triple helix recognition site in the hemopexin-like domains of human fibroblast and neutrophil interstitial collagenases. Ann. N.Y. Acad. Sci., 1994, 732, 22-30.
16. Murphy, G.; Alian, J.A.; Willenbrock, F.; Cockett, M.E; O'Connell, J.P.; Docherty, A.J.P. The role of the C-terminal domain in collagenase and stromelysin specificity. J. Biol. Chem., 1992, 267, 9612-9618.
17. Sanchez-Lopez, R.; Alexander, C.M.; Behrendtsen, O.; Breathnach, R.; Werb, Z. Role of zinc binding and hemopexin domain encoded sequences in the substrate specificity of collagenase and stromelysin- 2 by chimeric proteins. J. Biol. Chem., 1993, 268, 7238-7247.
18. Massova, I.; Kotra, L.P.; Fridman, R.; Mobashery, S. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J., 1998, 12, 1075-1095.
19. Mallya, S.K.; Mookhtiar, K.A.; Gao, Y.; Brew, K.; Dioszegi, M.; Birkedal-Hansen, H.; van Wart H.E. Characterization of 58- kilodalton human neutrophil collagenase: Comparison with human fibroblast collagenase. Biochemistry, 1990, 29, 10628-10634.
20. Lovejoy, B.; Welch, A.R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R.T.; Campbell, J.A.; Walker, K.A.; Martin, R.; van Wart, H.E.; Browner, M.F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol., 1999, 6, 217-221.
21. Fridman, R.; Fuerst, T.R.; Bird, R E.; Hoyhtya, M.; Oelkuct, M.; Kraus, S.; Komarek, D.; Liotta, L.A.; Berman, M.L.; Stetler- Stevenson, W.G. Domain structure of human 72-kDa gelatinase/ type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J. Biol. Chem., 1992, 267, 15398-15405.
22. Kaur, K.; Zhu, K.; Whittemore, M.S.; Petersen, R.L.; Lichte, A.; Tschesche, H.; Pourmotabbed, T. Identification of the active site of Gelatinase B as the structural element sufficient for converting a protein to a metalloprotease. Biochemistry, 2002, 41(15), 4789-4797.
23. Becker, J.W.; Marcy, A.I.; Rokosz, L.L.; Axel, M.G.; Burbaum, J.J.; Fitzgerald, P.M.; Cameron, P.M.; Esser, C.K.; Hagmann, W.K.; Hermes, J.D.; Springer, J.P. Stromelysin-1: threedimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci., 1995, 4, 1966-1976.
24. Pavlovsky, A.G.; Williams, M.G.; Ye, Q-Z.; Ortwine, D.F.; Purchase, C.F.II; White, A.D.; Dhanaraj, V.; Roth, B.D.; Johnson, L.L.; Hupe, D.; Humblet, C.; Blundell T.L. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci., 1999, 8, 1455-1462.
25. Ganea, E.; Trifan, M.; Laslo, A.C.; Putina, G.; Cristescu, C. Matrix metalloproteinases: useful and deleterious. Biochem. Soc. Trans., 2007, 35(4), 689-691.
26. Fernandez-Catalan, C.; Bode, W.; Huber, R.; Turk, D.; Calvete, J.J.; Lichte, A.; Tschesche, H.; Maskos, K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J., 1998, 17(17), 5238-5248.
27. Visse, R.; Nagase, H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circ. Res., 2003, 92(8), 827-839.
28. Gall, A.L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M.C.; Basset, P.; Moras D. Crystal structure of the stromelysin- 3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J. Mol. Biol., 2001, 307, 577-586.
29. Nar, H.; Werle, K.; Bauer, M.M.T.; Dollinger, H.; Jung, B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol., 2001, 312, 743-751.
30. Ye, S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol., 2000, 19, 623-629.
31. Corcoran, M.L.; Stetler-Stevenson, W.G.; DeWitt, D.L.; Wahl, L.M. Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes. Arch. Biochem. Biophys., 1994, 310, 481-488.
32. Galis, Z.; Muszynski, M.; Sukhova, G.K.; Simon-Morrissey, E.; Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. N.Y. Acad. Sci., 1995, 748, 501-507.
33. Siwik, D.A.; Chang, D.L.F.; Colucci, W.S. Interleukin-1b and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res., 2000, 86, 1259-1265.
34. Jormsjo, S.; Ye, S.; Moritz, J.; Walter, D.H.; Dimmeler, S.; Zeiher, A.M.; Henney, A.; Hamsten, A.; Eriksson P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res., 2000, 86, 998-1003.
35. Babčák, M.; Merčiaková, M.; Kmec, J.; Jenča, J. Diabetes mellitus 2. typ a artériová hypertenzia - najnovšie ponatky. Diabetes a obezita, 2004, 4, 15-41.
36. Duhamel-Clerin, E.; Orvain, C.; Lanza, F.; Cazenave, J.P.; Klein- Soyer, C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 1931-1938.
37. Ben-Yosef, Y.; Lahat, N.; Shapiro, S.; Bitterman, H.; Miller, A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/ reoxygenation. Circ. Res., 2002, 90, 784-791.
38. Huang, Y.; Song, L.; Wu, S.; Fan, F.; Lopes-Virella, M.F. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis, 2001, 156, 119-125.
39. Creemers, E.E.J.M.; Cleutjens, J.P.M.; Smits, J.F.M.; Daemen, M.J.A.P. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res., 2001, 89, 201-210.
40. Marx, N.; Schonbeck, U.; Lazar, M.A.; Libby, P.; Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res., 1998, 83, 1097-1103.
41. Chakraborti, S.; Mandal, M.; Das S.; Mandal, A.; Chakraborti, T. Regulation of matrix metalloproteinases: An overview. Mol. Cell. Biochem., 2003, 253, 269-285.
42. Li, Y.T.; McTiernan, C.F.; Feldman, A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res., 2000, 46, 214-224.
43. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of matrixmetalloproteinases: evolutioun, structure and function. Biochem. Biophys. Acta, 2000, 1477, 267-283.
44. Goldberg, G.I.; Strongin, A.; Collier, I.E.; Genrich, L.T.; Marmer, B.L. Interaction of 92-kDa type IV-collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase and activation of the proenzyme with stromelysin. J. Biol. Chem., 1992, 267, 4583-4591.
45. Li, Y.Y.; McTiernan, C.F.; Feldman, A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc. Res., 1999, 42, 162-172.
46. Chua, C.C.; Hamdy, R.C.; Chua, B.H.L. Angiotensin II induces TIMP-1 production in rat heart endothelial cells Biochim. Biophys. Acta, 1996, 1311, 175-180.
47. Fedak, P.W.M.; Smookler, D.S.; Kassiri, Z.; Ohno, N.; Leco, K.J.; Verma, S.; Mickle, D.A.G.; Watson, K.L.; Hojilla, C.V.; Cruz, W.; Weisel, R.D.; Li, R.K; Khokha, R. TIMP-3 Deficiency leads to dilated cardiomyopathy. Circulation, 2004, 110, 2401-2409.
48. Pavloff, N.; Staskus, P.W.; Kishnani, N.S.; Hawkes, S.P. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem., 1992, 267, 17321-17326.
49. Leco, K.J.; Apte, S.S.; Taniguchi, G.T.; Hawkes, S.P.; Khokha, R.; Schultz, G.A.; Edwards D.R. Murine tissue inhibitor of metalloproteinases- 4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett., 1997, 401, 213-217.
50. Schulze, C.J.; Wang, W.; Suarez-Pinzon, W.L.; Sawicka, J.; Sawicki, G.; Schulz, R. Imbalance between tissue inhibitor of metalloproteinase- 4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation, 2003, 107, 2487-2492.
51. Kandasamy, A.D.; Chow, A.K.; Ali, M.A.M.; Schulz, R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res., 2010, 85, 413-423.
52. Takahashi, C.; Sheng, Z.; Horan, T.P.; Kitayama, H.; Maki, M.; Hitomi, K.; Kitaura, Y.; Takai, S.; Sasahara, R.M.; Horimoto, A.; Ikawa, Y.; Ratzkin B.J.; Arakawa, T.; Noda, M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA., 1998, 95, 13221-13226.
53. Loftus, I.M.; Naylor, A.R.; Bell, P.R.F.; Thompson, M.M. Matrix metalloproteinases and atherosclerotic plaque instability. Br. J. Surg., 2002, 89, 680-94.
54. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ. Res., 2002, 90, 251-62.
55. Flamant, M.; Placier, S.; Dubroca, C.; Esposito, B; Lopes, I.; Chatziantoniou, C.; Tedgui, A.; Dussaule, J.C.; Lehoux, S. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension, 2007, 50, 212-218.
56. Dollery, C.M.; McEwan, J.; Henney, A. Matrix metalloproteinases and cardiovascular disease. Circ. Res., 1995, 77, 863-868.
57. Silence, J.; Lupu, F.; Collen, D.; Lijnen, H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol., 2001, 21(9), 1440-1445.
58. Silence, J.; Collen, D.; Lijnen, H.R. Reduced atherosclerotic plaque but enhanced aneurysm formationin mice with inactivation of the tissue inhibitor of matrixmetalloprotenase-1 (TIMP-1) gene. Circ. Res., 2002, 90, 897-903.
59. Galis, Z.S.; Johnson, C.; Godin, D.; Magid, R.; Shipley, J.M.; Senior, R.M.; Ivan, E. Targeted disruption of the matrix metalloproteinase- 9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res., 2002, 91, 852-859.
60. Sukhova, G.K.; Schoenbeck, U.; Rabkin, E.; Schoen, F.J.; Poole, A.R.; Billinghurst, R.C.; Libby, P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation, 1999, 99, 2503-2509.
61. Herman, M.P.; Sukhova, G.K.; Libby, P.; Gerdes, N.; Tang, N.; Horton, D.B.; Kilbride, M.; Breitbart, R.E.; Chun, M.; Schonbeck, U. Expression of neutrophil collagenase (matrix metalloproteinase- 8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation, 2001, 104, 1899-1904.
62. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 90, 775-778.
63. Schoenhagen, P.; Vince, D.G.; Ziada, K.M.; Kapadia, S.R.; Lauer, M.A.; Crowe, T.D.; Nissen, S.E.; Tuzcu, E.M. Relation of matrix metalloproteinase-3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am. J. Cardiol., 2002, 89, 1354-1359.
64. Pasterkamp, G.; Schoneveld, A.H.; Hijnen, D.J.; de Kleijn, D.P.V.; Teepen, H.; van der Wall, A.C.; Borst, C. Atherosclerotic arterialremodeling and the localization of macrophages and metalloproteases- 1,2, and 9 in the human coronary artery. Atherosclerosis, 2000, 150, 245-253.
65. Jalil, J.E.; Doering, C.W.; Janicki, J.S.; Pick, R.; Shroff, S.G.; Weber, K.T. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res., 1989, 64, 1041-1050.
66. Iwatsuki, K.; Cardinale, G.J.; Spector, S.; Udenfriend, S. Hypertension: increase of collagen biosynthesis in arteries but not in veins. Science, 1977, 198, 403-405.
67. Lindsay, M.; Maxwell, P.; Dunn, F. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension, 2002, 40, 136-141.
68. Sundström, J.; Evans, J.C.; Benjamin, E.J.; Levy, D.; Larson, M.G.; Sawyer, D.B.; Siwik, D.A.; Colucci, W.S.; Wilson, P.W.F.; Vasan, R.S. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J., 2004, 25, 1509-1516.
69. Laviades, C.; Varo, N.; Fernandez, J.; Mayor, G.; Gil, M.; Monreal, I.; Diez, J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation, 1998, 98, 535-540.
70. Ammarguellat, F.Z.; Gannon, P.O.; Amiri, F.; Schiffrin, E.L. Fibrosis, matrix metalloproteinases, and inflammation in heart of DOCA-salt hypertensive rats: Role of ETA receptors. Hypertension, 2002, 36, 679-684.
71. Tayebjee, M.H.; Nadar, S.; Blann, A.D.; Beevers, D.G.; MacFadyen, R.J.; Lip, G.Y.H. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment. A substudy of the angloscandinavian cardiac outcomes trial (ASCOT). Am. J. Hypertens., 2004, 17, 764-769.
72. Derosa, G.; D'Angelo, A.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.; Montagna, L.; Gravina, A.; Ferrari, I.; Galli, S.; Paniga, S.; Tinelli, C.; Cicero, A.F. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium, 2006, 13, 227-31.
73. Zervoudaki, A.; Economou, E.; Stefanadis, C.; Pitsavos, C.; Tsioufis, K.; Aggeli, C.; Vasiliadou, K.; Toutouza, M.; Toutouzas, P. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J. Hum. Hypertens., 2003, 17, 119-124.
74. Song, W.W.; Ergul, A. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: Relation to vessel size. Cardiovasc. Diabetol., 2006, 5, 3.
75. Harris, A.; Hutchinson, J.; Portik-Dobos, V.; Ergul, A. Decreased microvascular MMP activity in diabetes: relation to vascular remodeling and elevated endothelin-1. Cardiovasc. Pathol., 2004, 13, S85.
76. Death, A.K.; Fisher, E.J.; McGrath, K.C.Y.; Yue, D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis, 2003, 168, 263-269.
77. Shiau, M-Y.; Tsai, S-T.; Tsai, K-J.; Haung, M-L.; Hsu, Y-T.; Chang, Y-H. Increased Circulatory MMP-2 and MMP-9 Levels and Activities in Patients with Type 1 Diabetes Mellitus. MT Sinai J. Med., 2006, 73, 1024-1028.
78. Maxwell, P.R.; Timms, P.M.; Chandran, S.; Gordon, D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet. Med., 2001, 18, 777-780.
79. Derosa, G.; Avanzini, M.A.; Geroldi, D.; Fogari, R.; Lorini, R.; De Silvestri, A.; Tinelli, C.; Rondini, G.; d'Annunzio, G. Matrix metalloproteinase 2 may be a marker of macroangiopathy in children and adolescents with type 1 diabetes. Diabetes Care, 2004, 27, 273-274.
80. Baugh, M.D.; Gavrilovic, J.; Davies, I.R.; Hughes, D.A.; Sampson, M.J. Monocyte matrix metalloproteinase production in Type 2 diabetes and control - a cross sectional study. Cardiovasc. Diabetes, 2003, 2, 3.
81. Tayebjee, M.H.; McFayden, R.J.; Lim, H.S.; Lip, G.Y.H. Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes. Effect of 1 year's cardiovascular risk reduction therapy. Diabetes Care, 2004, 8, 2049-2051.
82. Lee, S.W.; Song, K.E.; Shin, D.S.; Ahn, S.M.; Ha, E.S.; Kim, D.J.; Nam, M.S.; Lee, K.W. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res. Clin. Pract., 2005, 69, 175-179.
83. Thrailkill, K.M.; Bunn, R.C.; Moreau, C.S.; Cockrell, G.E.; Simpson, P.M.; Coleman, H.N.; Frindik, J.P.; Kemp, S.F.; Fowlkes, J.L. Matrix Metalloproteinase-2 Dysregulation in Type I Diabetes. Diabetes Care, 2007, 30, 2321-2326.
84. Romanic, A.M.; Burns-Kurtis, C.L.; Ao, Z.; Arleth, A.J.; Ohlstein, E.H. Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am. J. Physiol. Renal. Physiol., 2001, 281, 309-317.
85. Jacqueminet, S.; Ben Abdesselam, O.; Chapman, M.J.; Nicolay, N.; Foglietti, M.J.; Grimaldi, A.; Beaudeux, J.L. Elevated circulating levels of matrix metalloproteinase-9 in type I diabetic patients with and without retinopathy. Clin. Chim. Acta., 2006, 367, 103-107.
86. Garvin, P.; Nilsson, L.; Carstensen, J.; Jonasson, L.; Kristenson, M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One, 2008, 3, e1774.
87. Cameron, V.A.; Rademaker, M.T.; Ellmers, L.J.; Espiner, E.A.; Nicholls, M.G.; Richards, A.M. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology, 2000, 141, 4690-4697.
88. Tsuruda, T.; Boerrigter, G.; Huntley, B.K.; Noser, J.A.; Cataliotti, A.; Costello-Boerrigter, L.C.; Chen, H.H.; Burnett, J.C. Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res., 2002, 91, 1127-1134.
89. Tamura, N.; Ogawa, Y.; Chusho, H.; Nakamura, K.; Nakao, K.; Suda, M.; Kasahara, M.; Hashimoto, R.; Katsuura, G.; Mukoyama, M.; Itoh, H.; Saito, Y.; Tanaka, I.; Otani, H.; Katsuki, M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA, 2000, 97, 4239-4244.
90. Lubos, E.; Schnabel, R.; Rupprecht, H.J.; Bickel, C.; Messow, C.M.; Prigge, S.; Cambien, F.; Tiret, L.; Münzel, T.; Blankenberg, S. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur. Heart J., 2006, 27, 150-156.
91. Jefferis, B.J.; Whincup, P.; Welsh, P.; Wannamethee, G.; Rumley, A.; Lennon, L.; Thomson, A.; Lawlor, D.; Carson, C.; Ebrahim, S.; Lowec, G. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis, 2010, 208, 557-563.
92. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L.E.; Schoen, F.J.; Kelly, R.A.; Werb, Z.; Libby, P.; Lee, R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest., 2000, 106, 55-62.
93. Prasad, A.; Tsimikas, S. Candidate Biomarkers for the Detection of Coronary Plaque Destabilization and Rupture. Curr. Atheroscler. Rep., 2008, 10, 309-317.
94. Hwang, J.J.; Yang, W.S.; Chiang, F.T.; Chen, M.F.; Lin, H.J.; Huang, P.J.; Hsu, S.H.; Lai, S.K.; Wu, Y.W. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis, 2009, 204, 293-7.
95. Nambi, V.; Morrison, A.C.; Hoogeveen, R.C.; Coresh, J.; Miles, S.; Rhodes, C.E.; Sharrett, A.R.; Boerwinkle, B.E.; Ballantyne, C.M. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex. Heart Inst. J., 2008, 35, 388-94.
96. Inoue, T.; Kato, T.; Takayanagi, K.; Uchida, T.; Yaguchi, I.; Kamishirado, H.; Morooka, S.; Yoshimoto, N. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am. J. Cardiol., 1992, 1461-1464.
97. Lehrke, M.; Greif, M.; Broed, U.C.; Lebherz, C.; Laubender, R.P.; Becker, A.; von Ziegler, H.; Tittus, J.; Reiser, M.; Becker, C.; Göke, B.; Steinbeck, G.; Leber, A.G.; Parhofer, K.G. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc. Diabetol., 2009, 8, 50.
98. Shah, P.K.; Galis, Z.S. Matrix Metalloproteinase Hypothesis of Plaque Rupture: Players Keep Piling Up But Questions Remain. Circulation, 2001, 104, 1878-1880.
99. Wilson, W.R.W.; Schwalbe, E.C.; Jones, J.L.; Bell, P.R.F.; Thompson, M.M. Matrix metalloproteinase 8 (neutrophil collagenase) inthe pathogenesis of abdominal aortic aneurysm. Br. J. Sur., 2005, 92, 828-833.
100. Kato, R.; Momiyama, Y.; Ohmori, R.; Taniguchi, H.; Nakamura, H.; Ohsuzu, F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J., 2005, 69, 1035-1040.
101. Turu, M.M.; Krupinski, J.; Catena, E.; Rosell, A.; Montaner, J.; Rubio, F.; Alvarez-Sabin, J.; Cairols, M.; Badimon, L. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis, 2006, 187, 161-169.
102. Tuomainen, A.M.; Nyyssönen, K.; Laukkanen, J.A.; Tervahartiala, T.; Tuomainen, T-P.; Salonen, J.T.; Sorsa, T.; Pussinen, P.J. Serum Matrix Metalloproteinase-8 Concentrations Are Associated With Cardiovascular Outcome in Men. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2722-2729.
103. Jones, J.A.; Zavadzkas, J.A.; Chang, E.I.; Sheats, N.; Koval, C.; Stroud, R.E.; Spinale, F.G.; Ikonomidis, J.S. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J. Thorac. Cardiovasc. Surg., 2010, 140, 653-659.
104. Pyo, R.; Lee, J.K.; Shipley, M.; Curci, J.A.; Mao, D.; Ziporin, S.J.; Ennis, T.L.; Shapiro, S.D.; Senior, R.M.; Thompson, R.W. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest., 2000, 105,1641-1649.
105. Maxwell, P.R.; Timms, P.M.; Chandran, S.; Gordon, D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes. Diabet. Med., 2001, 18, 777-780.
106. Lindsay, M.M.; Maxwell, P.; Dunn, F.G. TIMP-1 - a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension, 2002, 40, 136-41.
107. Timms, P.M.; Wright, A.; Maxwell, P.; Campbell, S.; Dawnay, A.B.; Srikanthan, V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am. J. Hypertens., 2002, 15, 269-272.
108. Li, Y.Y.; Feng, Y.; McTiernan, C.F.; Pei, W.; Moravec, C.S.; Wang, P.; Rosenblum, W.; Kormos, R.L.; Feldman, A.M. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation, 2001, 104, 1147-52.
109. Klotz, S.; Danser, A.H.J.; Foronjy, R.F.; Oz, M.C.; Wang, J.; Mancini, D.; D'Armiento, J.; Burkhoff, D. The Impact of Angiotensin- Converting Enzyme Inhibitor Therapy on the Extracellular Collagen Matrix During Left Ventricular Assist Device Support in Patients With End-Stage Heart Failure. J. Am. Coll. Cardiol., 2007, 49, 1166-1174.
110. Nanni, S.; Melandri, G.; Hanemaaijer, R.; Cervi, V.; Tomasi, L.; Altimari, A.; van Lent, N.; Tricoci, P.; Bacchi, L.; Branzi, A. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl. Res., 2007, 149,137-44.
111. Li, Y.Y.; Feldman, A.M.; Sun, Y.; McTiernan, C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98, 1728-1734.
112. Thomas, C.V.; Coker, M.L.; Zellner, J.L.; Handy, J.R.; Crumbley, A.J.; Spinale, F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with endstage dilated cardiomyopathy. Circulation 1998, 97, 1708-1715.
113. Schwartzkopff, B.; Fassbach, M.; Pelzer, B.; Brehm, M.; Strauer, B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur. J. Heart Fail., 2002, 4, 439.
114. Roten, L.; Nemoto, S.; Simsic, J.; Coker, M.L.; Rao, V.; Baicu, S.; Defreyte, G.; Soloway, P.J.; Zile, M.R.; Spinale, F.G. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase- type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol., 2000, 32, 109-120.
115. Myers, S.A. Tetracycline-Based MMP Inhibitors Can Prevent Fibroblast-Mediated Collagen Gel Contraction In vitro. Adv. Dent. Res., 1998, 12, 86-93.
116. Lindsey, M.; Lee, R.T. MMP inhibition as a potential therapeutic strategy for CHF. Drug News Perspect, 2000, 13, 350-354.
117. Dollery, C.M.; McEwan, J.R.; Henney, A.M. Matrix Metalloproteinases and Cardiovascular Disease. Circ. Res., 1995, 77, 863-868.
118. Spinale, F.G.; Coker, M.L.; Bond, B.R.; Zellner, J.L. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res., 2000, 46, 225-238.
119. Spinale, F.G.; Krombach, R.S.; Coker, M.L.; Mukherjee, R.; Thomas, C.V.; Houck, W.V.; Clair, M.J.; Kribbs, S.B.; Johnson, L.L.; Peterson, J.T. Matrix metalloproteinase inhibition during developing congestive heart failure in pigs, effects on left ventricular geometry and function. Circ. Res., 1999, 85, 364-376.
120. Bellosta, S.; Via, D.; Canavesi, M.; Pfister, P.; Fumagalli, R.; Paoletti, R.; Bernini, F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler., Thromb. Vasc. Biol., 1998, 18, 1671-1678.
121. Ikeda, U.; Shimpo, M.; Ohki, R.; Inaba, H.; Takahashi, M.; Yamamoto, K.; Shimada, K. Fluvastatin inhibits matrix metalloproteinase- 1 expression in human vascular endothelial cells. Hypertension, 2000, 36, 325-329.
122. Marx, N.; Froehlich, J.; Siam, L.; Ittner, J.; Wierse, G.; Schmidt, A.; Scharnagl, H.; Hombach, V.; Koenig, W. Antidiabetic PPARγ- Activator rosiglitazone reduces MMP-9 serum levels in Type 2 Diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 283-288.
123. Yiqin, Y.; Meilin, X.; Jie, X.; Keping, Z. Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARα/γ and TIMP- 1-mediated mechanisms in cultured mouse celiac macrophages. Inflammation, 2009, 32, 233-241.
124. MacFadyen, R.J. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? Curr. Opin. Pharmacol., 2007, 7, 171-178.
125. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.V.B. Broad-spectrum matrix metalloproteinase inhibitor marimastat induced muscular skeletal side effects in rats. Arthritis Rheumatol., 2003, 48, 1742-1749.
126. van der Laan, W.H.; Quax, P.H.; Seemayer, C.A.; Huisman, L.G.; Pieterman, E.J.; Grimbergen, J.M.; Verheijen, J.H.; Breedveld, F.C.; Gay, R.E.; Huizinga, T.W. Cartilage degradation and invasion by rheumatoid synovial fibroblasts in inhibited by gene transfer of TIMP-1 and TIMP 3. Gene Ther. 2003, 10, 234-242.
127. Moore, M.J.; Hamm, J.; Dancey, J.; Eisenberg, P.D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the national cancer institute of Canada clinical trials group. J. Clin. Oncol., 2003, 21, 3296-3302.
128. Almholt, K.; Juncker-Jensen, A.; Lærum, O.D.; Danø, K.; Johnsen, M.; Lund, L.R.; Rømer, R. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor galardin in the MMTV-PymT transgenic breast cancer model. Mol. Cancer Ther., 2008, 7, 2758-2767.
129. Wall, L.; Talbot, D.C.; Bradbury, P.; Jodrell, D.I. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br. J. Cancer, 2004, 90, 800-804.
130. Kaludercic, N.; Lindsey, M.L.; Tavazzi, B.; Lazzarino, G.; Paolocci, N. Inhibiting Met-aletal/et-alloproteases with PD 166793 in Heart Failure: Impact on Cardiac Remodeling and Beyond. Cardiovasc. Ther., 2008, 26, 24-37.
131. Kenagy, R.D.; Nikkari, S.T.; Welgus, H.G.; Clowes, A.W. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92 kD gelatinase and collagenase) in primate arterial smooth muscle cells. J. Clin. Invest., 1994, 93, 1987-1993.
132. Orbe, J.; Rodríguez, J.A.; Arias, R.; Belzunce, M.; Nespereira, B.; Pérez-Ilzarbe, M.; Roncal, C.; Páramo, J.A. Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis, 2003, 167, 45-53.
133. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87, 840-840.
134. Bond, M.; Chase, A.J.; Baker, A.H.; Newby, A.C. Inhibition of transcription factor NF-kB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res., 2001, 50, 556-563.
135. Ikeda, U.; Shimpo, M.; Ohki, R.; Inaba, H.; Takahashi, M.; Yamamoto, K.; Shimada, K. Fluvastatin inhibits matrix metalloproteinase- 1 expression in human vascular endothelial cells. Hypertension, 2000, 36, 325-329.
136. Xu, Z.; Zhao, S.; Zhou, H.; Ye, H.; Li, J. Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin. Chem., 2004, 50, 750-753.